NYSE:PFE News 1 October 2025

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior

31 October 2025

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlier ts2.tech – as investors grappled with

30 October 2025

Drug Pricing · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market · Trump Administration

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments

30 October 2025

Business · Investing · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:NVO · NYSE:PFE · Pharma News · Stock Market

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones

30 October 2025

Biotechnology · Industry News · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Drugs · Pharmaceuticals

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

PFE Stock Price and Recent Performance Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18%

27 October 2025

Business News · Health Industry · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

Record Highs on All Fronts, Led by Tech Stocks Friday’s broad rally sent all major U.S. indexes to fresh highs. The Dow’s 400‑point gain topped the largest single‑day jump of 2025, while the S&P 500 and Nasdaq also closed at

24 October 2025

Economic News · Federal Reserve · Inflation · NASDAQ:AAPL · NASDAQ:AMD · NASDAQ:INTC · NASDAQ:MSFT · NASDAQ:MU · NASDAQ:NVDA · NYSE:BA · NYSE:CVX · NYSE:KO · NYSE:PFE · NYSE:XOM · Stock Market · Tech Stocks

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior

19 October 2025

Business News · Investment · Market Analysis · NASDAQ:MTSR · NYSE:PFE · Pharmaceuticals · Stocks

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Key Facts – October 18, 2025 Nasdaq Ends Week Higher Amid Roller-Coaster Trading After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday

18 October 2025

Financial News · Investing · Market Analysis · NASDAQ:AMD · NASDAQ:AVGO · NASDAQ:KLAC · NASDAQ:NVDA · NASDAQ:WAL · NASDAQ:ZION · NYSE:LLY · NYSE:PFE · Stock Market · Technology

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a

6 October 2025

Business News · Healthcare · Investment Trends · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharma Industry · Stock Market

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Market commentary and outlook Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report

2 October 2025

Economic News · Finance · Market Trends · NASDAQ:MU · NASDAQ:STX · NASDAQ:WDC · NYSE:AES · NYSE:LLY · NYSE:PFE · Stock Market · U.S. Economy

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring

2 October 2025

Business Trends · Healthcare News · Investing · NYSE:PFE · Pharmaceutical Industry · Stock Market

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell,

1 October 2025

Economic News · Financial Trends · Investment Insights · Market Analysis · NASDAQ:AZN · NASDAQ:BIIB · NYSE:LLY · NYSE:PFE · NYSE:TMO · Stock Market

NYSE:PFE News 1 October 2025 - 31 October 2025